Capmatinib (Everest)
Original price was: £512.00.£429.00Current price is: £429.00.
Capmatinib (Capmatinib) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Capmaxen by Everest Pharma is a high-quality generic version of Capmatinib, offering patients a more affordable treatment option. MedFind provides overseas sourcing services for Capmatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Product Overview
Capmatinib (Brand name: Tabrecta) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Indications
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.
Dosage and Administration
- Recommended dosage: 400 mg twice daily
- May be taken with or without food
- Swallow tablets whole; do not chew, crush, or split
- If severe adverse reactions occur, consult a healthcare professional regarding dose adjustment
Possible Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Constipation
- Diarrhea
- Edema
- Fatigue
- Cough
- Decreased appetite
- Rash
If serious adverse reactions occur, discontinue use immediately and seek medical attention.
Precautions
- Regular monitoring of liver function and blood counts is recommended during treatment
- Not recommended for use during pregnancy or breastfeeding
- Avoid grapefruit or grapefruit juice due to potential drug interactions
- Do not adjust dosage without medical guidance
Storage
Store at room temperature (20–25°C), away from direct sunlight and moisture, and keep out of reach of children.
RELATED PRODUCTS
Adagrasib (Everest)
Original price was: £512.00.£461.00Current price is: £461.00.
Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.
Gilteritinib / Xospata (Everest)
Original price was: £412.00.£396.00Current price is: £396.00.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00
Reviews
There are no reviews yet.